LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/RTI Surgical Beefs Up With Two Top Industry Vets
Company News

RTI Surgical Beefs Up With Two Top Industry Vets

December 20, 2019 2 min read Premium comments

Advertisement

RTI Surgical Beefs Up With Two Top Industry Vets
(L to R): Terry Rich, RTI Surgical Holdings, Inc. and Olivier Visa / Courtesy of RTI Surgical Holdings, Inc.
Secondary#alphatec#rtisurgical

Terry Rich, who played a pivotal role in the turnaround of Alphatec Spine, has been named president of Global Spine at RTI Surgical Holdings, Inc. In addition, Olivier Visa has been promoted to president of Global OEM.

Mr. Rich, as a director and CEO of Alphatec Spine, strengthened the organization’s competencies and, according to RTI Surgical, redirected the portfolio with 12 new products and laid the foundation for focused innovation and growth. Before joining Alphatec Spine, Rich was president of Upper Extremities at Wright Medical Group, N.V. Rich had previously held sales leadership positions at Tornier, NuVasive and DePuy Spine.

“This is an important appointment that adds a globally recognized leader to the helm of our spine segment at RTI,” said Camille Farhat, company president and CEO. “Terry has a deep commitment to growth and innovation, as well as exceptional relationships with clinical thought leaders in our market. Our spine business is in the early stages of what we believe is a longer-term transformation with tremendous opportunities ahead. We believe Terry’s leadership will help accelerate the execution of our Novel Therapies commercial channel and multiple product launches planned for 2020.”

According to RTI, “Visa joined RTI in October 2017 as vice president of OEM and has spearheaded the positive performance of this business segment within RTI. Under his leadership, the OEM segment has earned a solid market position serving leading medical technology companies that operate in a diverse set of end markets with attractive growth profiles. Over the past two years the business has returned to growth, driven operational excellence and delivered significant predictable recurring EBITDA.”

Terry Rich told OTW, “I am thrilled to be joining RTI Surgical as the leader of the global spine business with a heightened focus on strengthening our commercial channels, globalizing our portfolio, advancing our product development pipeline and integrating new technologies to enable physician partners to deliver better outcomes. My immediate focus is getting up to speed on our teams, key customers, operating plan, current portfolio, R&D pipeline and international markets. I am eager to meet folks face-to-face over the next few weeks. This is an exciting time for our spine business as we are gaining momentum and have much to look forward to in 2020.”

Olivier Visa, who will be RTI’s new president of Global OEM, told OTW that, “Going forward, our priorities center around improving customer intimacy and pursuing focused innovation of products and services. We have tremendous opportunity to leverage our deep expertise in design, private label product development, manufacturing and processing to expand our customer partnerships and fulfill our deep product pipeline.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy